Lupin is currently trading at Rs. 771.00, up by 7.90 points or 1.04% from its previous closing of Rs. 763.10 on the BSE.
The scrip opened at Rs. 763.50 and has touched a high and low of Rs. 779.50 and Rs. 753.60 respectively. So far 71744 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1194.00 on 15-Jun-2017 and a 52 week low of Rs. 723.55 on 15-May-2018.
Last one week high and low of the scrip stood at Rs. 798.00 and Rs. 748.95 respectively. The current market cap of the company is Rs. 34935.54 crore.
The promoters holding in the company stood at 47.01%, while Institutions and Non-Institutions held 37.60% and 15.40% respectively.
Lupin has launched Methylergonovine Maleate Tabs USP, 0.2 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Methylergonovine Maleate Tabs USP, 0.2 mg, had annual sales of approximately $71.5 million in the US (IQVIA MAT April 2018).
Lupin’s Methylergonovine Maleate Tabs USP, 0.2 mg, is the generic equivalent of Novartis Pharmaceuticals Corporation’s Methergine. It is indicated for the prevention and control of postpartum hemorrhage.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
